Login to Your Account



Emmaus' Endari wins FDA nod; first new SCD drug in nearly 20 years

By Jennifer Boggs
Managing Editor

Friday, July 7, 2017

Emmaus Medical Inc.'s pharmaceutical-grade L-glutamine cleared the FDA on its July 7 PDUFA date, becoming the first new treatment for sickle cell disease in the U.S. since chemotherapeutic agent hydroxyurea gained approval in 1998.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription